Liver Fibrosis Market Report and Forecast 2024-2032

Liver Fibrosis Market Outlook

The liver fibrosis market size was valued at USD 2317.7 million in 2023, driven by the increasing incidence and awareness of liver fibrosis among people. The market size is anticipated to grow at a CAGR of 7.7% during the forecast period of 2024-2032 to achieve a value of USD 4518.6 million by 2032.

Liver Fibrosis: Introduction

Fibrosis refers to the thickening or scarring of tissues. Fibrosis makes the essential structures of the liver lose their delicacy, followed by which they become thick, stiff, and scarred. When it comes to the liver, fibrosis involves the excessive formation of scar tissue. This occurs when the liver undergoes attempts at self-repair and cell replacement due to damage. Typically, after a singular instance of injury, such as with acute hepatitis, the liver's natural response involves generating new cells and integrating them into the remaining connective tissue framework, left behind after cell death.

However, in cases of repeated or ongoing damage, as observed in chronic hepatitis, the liver's repair efforts result in the formation of scar tissue—fibrosis. Fibrosis signifies an abnormal response to damage, wherein the body's attempt at healing leads to the formation of scar tissue, altering the structure and functionality of the affected organ.

Liver Fibrosis Market Analysis

The liver fibrosis market is experiencing significant market growth driven by the increased prevalence of liver fibrosis. The market growth is also driven by several innovations and novel therapies targeted toward treating such complex conditions. A recent update by Intercept Pharmaceuticals on the FDA accepting their New Drug Application (NDA) for obeticholic acid (OCA) marks a pivotal moment in addressing pre-cirrhotic liver fibrosis due to non-alcoholic steatohepatitis (NASH). This acceptance by the FDA not only expands treatment options but also fills a crucial gap, offering the first approved treatment specifically targeting this stage of liver fibrosis. The competitive landscape is expected to evolve with the introduction of other drugs like OCA and resmethrin, as both are known to address the same concern with different mechanisms, further influencing the liver fibrosis market growth.

Researchers are delving deep into various approaches, exemplified by the exploration of a hormone-mimicking drug by the University of California San Diego School of Medicine, that showcased promising results, demonstrating improvements in liver fibrosis and inflammation among NASH patients. This study underscores the dedication and depth of comprehension researchers are demonstrating in their efforts to provide effective treatments for this condition, which currently lacks approved therapies. These increasing innovations and advancements are exhibiting further potential markets for growth in the forecast period. The focused efforts of pharmaceutical companies, coupled with research institutions, indicate a growing understanding of the complexities of liver fibrosis exhibiting the need for new treatment approaches and drug pipelines.

Liver Fibrosis Market Segmentations

Market Breakup by Condition

• Chronic Liver Diseases

• Hepatitis C

• Nonalcoholic Steatohepatitis

Market Breakup by Treatment

• Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist

• ACE Inhibitors

• Hepatotropic Drug

• Others

Market Breakup by Distribution Channel

• Hospital Pharmacies

• Retail Stores and Pharmacy

• Online Providers

Market Breakup by End User

• Hospitals

• Clinics

• Others

Market Breakup by -7MM

• United States

• EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom

• Japan

Liver Fibrosis Market Overview

The market in the 7 major markets is witnessing substantial growth propelled by the escalating prevalence of liver-related conditions worldwide. The increasing efforts of research organizations focusing on developing treatments for fatty liver diseases are also expected to further propel the liver fibrosis market growth significantly.

Moreover, the rising mortality rates due to liver diseases and the increasing incidence of liver cancer emphasize the urgent need for advanced treatments. The data from the United States substantial data exhibits how there is an existing urgent demand for effective treatments and interventions in the market to address the growing health concerns associated with liver diseases.

Liver Fibrosis Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• F. Hoffmann-La Roche

• Mylan N.V.

• Sanofi

• GlaxoSmithKline plc

• AstraZeneca

• Johnson & Johnson

• Merck & Co.

• Bristol-Myers Squibb

• Vertex Pharmaceuticals

• FibroGen, Inc.

• Pharmaxis

• Dicerna Pharmaceuticals, Inc.

• Dynavax Technologies

• GlaxoSmithKline plc

Please note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report